What's New

Last Posted: Sep 07, 2023

• [Prognosis of overall and disease-free survival in patients with grade 3 astrocytomas (anaplastic astrocytoma, WHO 2016)].
  A Yu Belyaev, et al. Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko 2023 0 (4) 46-57
• [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
  Liu Q Q, et al. Zhonghua bing li xue za zhi = Chinese journal of pathology 2018 0 (9) 658-663
• Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
  Hong Bujung, et al. Acta neurochirurgica 2018 0 (11) 2237-2248
• Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
  Iuchi Toshihiko, et al. Brain tumor pathology 2018 0 (2) 71-80
• Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
  Kwon Mi Jung, et al. Brain pathology (Zurich, Switzerland) 2019 0 (2) 235-245
• Cerebellar anaplastic astrocytoma in adult patients: 15 consecutive cases from a single institution and literature review.
  Belyaev Artem, et al. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021 0 249-254
• Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.
  Ruiz María Fernanda, et al. Molecular and clinical oncology 2021 0 (2) 150
• Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
  Tesileanu C Mircea S, et al. Neuro-oncology 2021 0 (9) 1547-1559
• SNP-based detection of allelic imbalance: A novel approach for identifying KIAA1549-BRAF fusion in pilocytic astrocytoma using DNA sequencing.
  Bobach Ida Schwartz, et al. Experimental and molecular pathology 2021 0 104621
• Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity.
  Eschbacher Kathryn L, et al. The American journal of surgical pathology 2021 0 (8) 1082-1090
• H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
  Bin-Alamer Othman, et al. World neurosurgery 2022 0 e251-e264
• Can quantifying the extent of 'high grade' features help explain prognostic variability in anaplastic astrocytoma?
  Goacher Edward, et al. British journal of neurosurgery 2020 0 1-8
• Genetic signature and treatment of pediatric high-grade glioma.
  Guidi Milena, et al. Molecular and clinical oncology 2021 4 (4) 70
• Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
  Munisamy Murali, et al. The pharmacogenomics journal 2021 2
• ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
  Kim Nalee, et al. Radiation oncology (London, England) 2020 7 (1) 184
• The role of ABO blood groups in glial neoplasms.
  Alkan Ali, et al. British journal of neurosurgery 2019 2 (1) 43-46
• Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
  Kuwahara Kiyonori, et al. Brain tumor pathology 2019 7
• IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population.
  Chatterjee Debajyoti, et al. Surgical neurology international 2018 0 29
• The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
  Lee Yujin, et al. Acta neuropathologica communications 2017 8 (1) 62
• Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
  Rajmohan K S, et al. Journal of clinical pathology 2016 1
• The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
  Kizilbash Sani H, et al. Journal of neuro-oncology 2014 10 (1) 85-93
• Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
  Ogura Ryosuke, et al. Neuropathology : official journal of the Japanese Society of Neuropathology 2015 8 (4) 324-35
• Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
  Chen J-R, et al. Acta neurologica Scandinavica 2015 4
• IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
  Minniti Giuseppe, et al. Journal of neuro-oncology 2014 6 (2) 377-83
• Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
  Zhang Chuan-Bao, et al. Journal of cancer research and clinical oncology 2014 1 (1) 45-51
• 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
  Jiang H, et al. Neuro-oncology 2013 3
• IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
  Thota Balaram, et al. American journal of clinical pathology 2012 8 (2) 177-84
• DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
  Motomura Kazuya, et al. Journal of neuropathology and experimental neurology 2012 8 (8) 702-7
• Anaplastic astrocytoma
  From NCATS Genetic and Rare Diseases Information Center
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
  Hartmann Christian, et al. Acta neuropathologica 2010 12 (6) 707-18
• MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
  Groenendijk Floris H, et al. Journal of neuro-oncology 2011 2 (3) 405-17
• Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.
  Kilburn Lindsay, et al. Cancer 2010 5 (9) 2242-9
• Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
  Antonelli Manila, et al. Journal of neuro-oncology 2010 9 (2) 209-15
• Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
  Sonoda Yukihiko, et al. Cancer science 2009 10 (10) 1996-8
• IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
  Nobusawa Sumihito, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2009 10 (19) 6002-7
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
  Watanabe Takuya, et al. The American journal of pathology 2009 4 (4) 1149-53
• Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations.
  Watanabe Takuya, et al. Journal of neuropathology and experimental neurology 2009 2 (2) 210-5
• Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
  Wiencke John K, et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005 7 (7) 1774-83
• Glutathione S-transferase polymorphisms and survival in primary malignant glioma.
  Okcu MF, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2004 4 (8) 2618-25
• Lack of association of rare alleles in the HRAS variable number of tandem repeats (VNTR) region with adult glioma.
  Chen P, et al. Neuro-oncology 2000 4 (2) 120-4

More